Focused On-demand Library for Mitochondrial disaggregase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Suppressor of potassium transport defect 3

Alternative UPACC:

Q9H078; B4DXJ7; B4DXP7; B4DXW4; E7EWN6; F8W7P6; Q8ND11; Q9H8Y0


The Mitochondrial disaggregase, also known as Suppressor of potassium transport defect 3, plays a crucial role in cellular homeostasis. It functions as a regulatory ATPase involved in secretion/protein trafficking processes and has ATP-dependent protein disaggregase activity. This protein is essential for maintaining the solubility of key mitochondrial proteins and is involved in mitochondrial-mediated antiviral innate immunity.

Therapeutic significance:

Linked to diseases such as 3-methylglutaconic aciduria 7B and 7A, and severe congenital neutropenia 9, understanding the role of Mitochondrial disaggregase could open doors to potential therapeutic strategies. Its involvement in granulocyte differentiation highlights its potential in treating immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.